

Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)* of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Oversight and Government Reform

Subcommittee: _____

Hearing Date: 06/10/2025

Hearing Subject:

"Securing Americans' Genetic Information: Privacy and National Security Concerns Surrounding 23andMe's Bankruptcy Sale"

Witness Name: Mr. Joseph Selsavage

Position/Title: Interim Chief Executive Officer and Chief Financial and Accounting Officer

Witness Type: ☐ Governmental ☒ Non-governmental

Are you representing yourself or an organization? ☐ Self ☒ Organization

If you are representing an organization, please list what entity or entities you are representing:

23andMe Holding Co.

FOR WITNESSES APPEARING IN A NON-GOVERNMENTAL CAPACITY

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

Are you a fiduciary—including, but not limited to, a director, officer, advisor, or resident agent—of any organization or entity that has an interest in the subject matter of the hearing? If so, please list the name of the organization(s) or entities.

Yes. I am an executive officer of 23andMe Holding Co.

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.

1. There is a Negotiated Service Agreement (NSA) with U.S. Postal Service providing for reduced rates for Priority Mail and USPS Ground Advantage. This agreement optimizes inbound and outbound logistics for consumer test kits and Lemonaid prescription shipments.
2. There is a contract with the National Cancer Institute which allows 23andMe to use a mouse cell line (COL38) for internal cancer-related therapeutics research. There are no on-going activities at 23andMe related to this work.
3. There is a contract with the U.S. Department of Health and Human Services, as represented by the National Institute of Allergy and Infectious Diseases which allows 23andMe to use a cancer-derived cell line for internal cancer-related therapeutics research. There are no on-going activities at 23andMe related to this work.
4. There is a license agreement with the National Institute of Health contract is a license agreement to use the Metathesaurus database, and was used in relation to internal data analytics by 23andMe.
5. 23andMe received a grant from the National Institute of General Medical Sciences (part of the National Institutes of Health) for a project titled "Scalable methods for the characterization and analysis of families in large genomic datasets". In this project we were developing ways of identifying relatives and building family trees in computationally efficient ways (i.e., so that we can run the methods on large numbers of people without breaking the bank on compute costs). This grant was initially awarded to Dr. Amy Williams in 2019 when she was still faculty at Cornell University. When Dr. Williams joined 23andMe in 2022, she brought the grant with her, so 23andMe received a total of \$533,292 from the grant between 8/1/2022 and 7/31/2024, when the project ended. For reference, the NIH project number is 7R35GM133805.

Please list any contracts, grants, or payments originating with a foreign government and related to the hearing's subject that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the amount and country of origin of each contract or payment.

None.

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

- ☒ I have attached a written statement of proposed testimony.
- ☒ I have attached my curriculum vitae or biography.

* Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

(5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.

(B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include— (i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing.

(C) The disclosure referred to in subdivision (B)(ii) shall include— (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.

(D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

False Statements Certification

Knowingly providing material false information to this committee/subcommittee, or knowingly concealing material information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). This form will be made part of the hearing record.



Witness signature

June 6, 2025

Date